Flare Therapeutics

About

Flare Therapeutics is a clinical-stage biotechnology company exclusively focused on drugging transcription factors - a previously elusive target class that represents one of the most significant opportunities in modern medicine. Founded in 2021 and headquartered in Cambridge, Massachusetts, Flare Therapeutics is revolutionizing cancer treatment by targeting "switch sites" to regain transcriptional control and develop cutting-edge medicines for patients. The company's integrated discovery engine converges rich genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule therapies. Their lead program, FX-909, is a first-in-class orally available small molecule inhibitor of PPARG, a master regulator of the luminal lineage, initially being developed for advanced urothelial cancer. FX-909 has achieved clinical proof-of-concept in a Phase 1A study and is actively dosing patients in Phase 1B. Their second lead program, FX-111, is a novel degrader targeting ARON for prostate cancer. With a partnership with Roche and a rich discovery pipeline across multiple therapeutic areas, Flare Therapeutics is trailblazing a path to the possible for novel therapies.